Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database DOI
Zhanzhang Wang, Haoyang Lu,

Yuandan Li

и другие.

British Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 29, 2024

Abstract Aims This study aimed to provide a comprehensive view of cardiovascular adverse events (AEs) associated with venlafaxine (VEN) therapy. Methods Cardiovascular AE reports for patients receiving VEN therapy were retrieved from January 2004 December 2023 the FDA Adverse Event Reporting System database. Effects age, sex and daily dose on occurrence different types AEs influence demographics, dose, comorbidity co‐medication death in analysed by multivariate logistic regression analysis. Results The included 16 110 following treatment (median age: 51 years, females: 69.78%, median dose: 100 mg/day). was increased risks cardiac arrhythmias, embolic thrombotic events, torsade de pointes/QT prolongation, ischaemic heart disease, failure, cardiomyopathy overall events. elderly (≥ 75 years), male sex, (infections infestations, disorders, nervous system disorders) (quetiapine clozapine) related VEN‐associated AEs; however, risk did not increase regular doses. Conclusions Our confirmed association revealed influencing factors VEN‐related due these Based obtained evidence, health late‐elderly complex polytherapy should be closely monitored when they receive As an exploratory study, prospective studies are needed validate our findings future.

Язык: Английский

Depression and Anxiety Disorders DOI
Oğuz Karamustafalıoğlu,

Hüseyin Yumrukçal

Опубликована: Апрель 10, 2025

Abstract Depression (major depressive disorder) is widely recognised as a major public health problem around the world. The mainstay of treatment prescription antidepressants, although psychological treatments have place first‐line alternative to antidepressants in milder and moderate forms depression. This chapter concentrates on use offers advice drug choice, dosing, switching strategies sequencing treatments. near exclusion other non‐drug modalities does not imply any lack confidence their efficacy but simply reflects need (in prescribing guideline) concentrate medicines‐related subjects. Antidepressants are number anxiety spectrum disorders. Use selective serotonin reuptake inhibitors (SSRIs) preoperative period has been associated with 20% increase inpatient mortality, patient factors rather than could be excluded cause.

Язык: Английский

Процитировано

7

Safety of Edaravone in real-world use: analysis based on FDA adverse event reporting system DOI
Tao Peng, Nan Hu, Lan Huang

и другие.

Expert Opinion on Drug Safety, Год журнала: 2025, Номер unknown

Опубликована: Фев. 21, 2025

Edaravone is a novel free radical scavenger utilized to treat amyotrophic lateral sclerosis (ALS). However, long-term safety data remain limited. Adverse event reports related edaravone from the second quarter of 2017 2024 were extracted US Food and Drug Administration (FDA) Event Reporting System database (FAERS). Disproportionality analysis was conducted utilizing reporting odds ratio (ROR), proportional (PRR), Bayesian confidence propagation neural network (BCPNN), multi-item gamma Poisson shrinker (MGPS) algorithms. A total 3,149 adverse analyzed. The most common reactions included systemic disorders administration site reactions, nervous system disorders, respiratory surgical medical procedures. New reaction signals disseminated intravascular coagulation, gastric fistula, sputum retention, excessive salivation, fractures, elevated cystatin C. median onset time for events 43 days (interquartile range: 7-173 days). This study confirmed previously reported identified several new ones associated with edaravone. These findings provide valuable insights optimizing ALS patient management highlight need further research into mechanisms these reactions.

Язык: Английский

Процитировано

0

Examining the Long-Term Impacts of Psychotropic Drugs and Considerations for People Discontinuing Treatment DOI Creative Commons
Timothy Wand

Issues in Mental Health Nursing, Год журнала: 2025, Номер unknown, С. 1 - 9

Опубликована: Март 21, 2025

Psychotropic drugs dominate the mental healthcare landscape. This is despite contention over their proposed mechanism of action, concerns for adverse effects, and questionable effectiveness, especially long term. Mental health nurses are routinely involved in administering psychotropic drugs, observing managing providing information support to people prescribed these agents. critique explores current understanding action evidence effect burden implications term use. The role deprescribing supporting discontinue treatment considered.

Язык: Английский

Процитировано

0

Effects of age, sex, daily dose, comorbidity and co‐medication on venlafaxine‐associated cardiovascular adverse events: A pharmacovigilance analysis of the FDA Adverse Event Reporting System database DOI
Zhanzhang Wang, Haoyang Lu,

Yuandan Li

и другие.

British Journal of Clinical Pharmacology, Год журнала: 2024, Номер unknown

Опубликована: Окт. 29, 2024

Abstract Aims This study aimed to provide a comprehensive view of cardiovascular adverse events (AEs) associated with venlafaxine (VEN) therapy. Methods Cardiovascular AE reports for patients receiving VEN therapy were retrieved from January 2004 December 2023 the FDA Adverse Event Reporting System database. Effects age, sex and daily dose on occurrence different types AEs influence demographics, dose, comorbidity co‐medication death in analysed by multivariate logistic regression analysis. Results The included 16 110 following treatment (median age: 51 years, females: 69.78%, median dose: 100 mg/day). was increased risks cardiac arrhythmias, embolic thrombotic events, torsade de pointes/QT prolongation, ischaemic heart disease, failure, cardiomyopathy overall events. elderly (≥ 75 years), male sex, (infections infestations, disorders, nervous system disorders) (quetiapine clozapine) related VEN‐associated AEs; however, risk did not increase regular doses. Conclusions Our confirmed association revealed influencing factors VEN‐related due these Based obtained evidence, health late‐elderly complex polytherapy should be closely monitored when they receive As an exploratory study, prospective studies are needed validate our findings future.

Язык: Английский

Процитировано

2